Aprea Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Aprea Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Doylestown
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- APRE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001781983
Board of directors
-
Bernd R. Seizinger · DirectorSince 2023
-
Gabriela Gruia · DirectorSince 2023
-
Jean-Pierre Bizzari · DirectorSince 2023
-
John B. Henneman III · DirectorSince 2023
-
Marc Duey · DirectorSince 2023
-
Michael Grissinger · DirectorSince 2023
-
Oren Gilad · Director · President/CEOSince 2023
-
Richard Peters · DirectorSince 2023
-
Rifat Pamukcu · DirectorSince 2023
Chief executives
Oren Gilad
· President, CEO
Dates unknown
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
93.4%
-
98.9%
-
99.0%
Board connections
5 of this board's directors also sit on 9 other boards.
- via Jean-Pierre Bizzari
- via Michael Grissinger
- via Michael Grissinger
- via John B. Henneman III
- via Jean-Pierre Bizzari
- via Michael Grissinger
- via Bernd R. Seizinger
- via John B. Henneman III
- via Gabriela Gruia
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $61,039
- 4 purchases by 3 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Michael Grissinger Director | Grant or award | +3,135 | — | — |
| Jun 16, 2026 | Gabriela Gruia Director | Grant or award | +3,135 | — | — |
| Jun 16, 2026 | Richard Peters Director | Grant or award | +3,135 | — | — |
| Jun 16, 2026 | John B. Henneman III Director | Grant or award | +3,135 | — | — |
| Jun 16, 2026 | Jean-Pierre Bizzari Director | Grant or award | +3,135 | — | — |
| Jun 16, 2026 | Marc Duey Director | Grant or award | +3,135 | — | — |
| Jun 16, 2026 | Rifat Pamukcu Director | Grant or award | +3,135 | — | — |
| Jun 16, 2026 | Bernd R. Seizinger Director | Grant or award | +3,135 | — | — |
| Mar 12, 2026 | Oren Gilad Director, Officer (President/CEO) | Grant or award | +20,175 | — | — |
| Mar 12, 2026 | Hamill John P. Officer (SrVP/CFO/Prin Fin & Acct Ofcr) | Grant or award | +10,095 | — | — |
| Jan 30, 2026 | Oren Gilad Director, Officer (President/CEO) | Open-market purchase | +28,100 | $0.89 | $25,009 |
| Jan 30, 2026 | Hamill John P. Officer (SrVP/CFO/Prin Fin & Acct Ofcr) | Open-market purchase | +5,700 | $0.89 | $5,073 |
| Dec 10, 2025 | Marc Duey Director | Open-market purchase | +21,459 | $1.17 | $25,107 |
| Dec 10, 2025 | Hamill John P. Officer (SrVP/CFO/Prin Fin & Acct Ofcr) | Open-market purchase | +5,000 | $1.17 | $5,850 |
| Jun 5, 2025 | Bernd R. Seizinger Director | Grant or award | +1,045 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.